A5066384705- Bladder and Urothelial Cancer Treatments
- Prostate Cancer Treatment and Research
- Nanoparticle-Based Drug Delivery
- Urinary and Genital Oncology Studies
- Peptidase Inhibition and Analysis
- Nanoplatforms for cancer theranostics
- Lung Cancer Research Studies
- Neuroendocrine Tumor Research Advances
- Monoclonal and Polyclonal Antibodies Research
- Lymphoma Diagnosis and Treatment
- Immunotherapy and Immune Responses
- Chronic Lymphocytic Leukemia Research
- Neuroblastoma Research and Treatments
- Cancer Immunotherapy and Biomarkers
- Advanced Breast Cancer Therapies
- Ferroptosis and cancer prognosis
- Radiopharmaceutical Chemistry and Applications
- FOXO transcription factor regulation
- Lung Cancer Treatments and Mutations
- Receptor Mechanisms and Signaling
- Cholesterol and Lipid Metabolism
- CAR-T cell therapy research
- Ubiquitin and proteasome pathways
- Cancer-related gene regulation
- Fullerene Chemistry and Applications
University of California, San Francisco
2012-2024
Peking University
2015-2024
Peking University Cancer Hospital
2015-2024
City College of San Francisco
2023-2024
Wuhan University
2021-2023
Renmin Hospital of Wuhan University
2021-2023
UCSF Helen Diller Family Comprehensive Cancer Center
2021-2022
Xijing Hospital
2021
Air Force Medical University
2021
Anhui University of Technology
2021
Enfortumab vedotin (EV) is an antibody-drug conjugate (ADC) targeting NECTIN4 (encoded by the PVRL4/NECTIN4 gene) approved for treatment-refractory metastatic urothelial cancer. Factors that mediate sensitivity or resistance to EV are unknown. In this study, we sought (i) examine heterogeneity of gene expression across molecular subtypes bladder cancer and (ii) determine whether mediates resistance.Molecular subtyping data from seven muscle-invasive clinical cohorts (n = 1,915 total...
Abstract Effective treatments for de novo and treatment-emergent small-cell/neuroendocrine (t-SCNC) prostate cancer represent an unmet need this disease. Using metastatic biopsies from patients with advanced cancer, we demonstrate that delta-like ligand 3 (DLL3) is expressed in t-SCNC associated reduced survival. We develop a PET agent, [89Zr]-DFO-DLL3-scFv, detects DLL3 levels mouse SCNC models. In multiple patient-derived xenograft models, AMG 757 (tarlatamab), half-life–extended...
<p>Supplementary Figure S23. Organ biodistribution presented in (left) %ID/g, and (right) %ID/organ of 89Zr labeled nanocarriers nude mice inoculated with 22rv1 cells via intracardiac injection at 72 h postinjection. (n = 4, mean ± SD)</p>
<p>Supplementary Figure S7. Coronal μPET/CT fusion and MIP images obtained at 24 h, 48 72 96 h following administration of 150-170 μCi 89Zr labeled nanocarriers in nude mice bearing LTL-610 patient derived xenograft (PDX) tumors over left flanks.</p>
<p>Supplementary Figure S11. Organ biodistribution presented in (left) %ID/g, and (right) %ID/organ for 89Zr labeled nanocarriers nude mice bearing LTL-610 patient derived xenograft (PDX) of tumors at 96 h postinjection. (n = 4, mean ± SD)</p>
<p>Supplementary Figure S4. Coronal μPET/CT fusion and MIP images obtained at 18 h, 48 72 96 h following administration of 150-170 μCi 89Zr labeled nanocarriers in nude mice bearing 22rv1 subcutaneous tumors over left flanks.</p>
<p>Supplementary Figure S22. BLI of all mice in the cohort inoculated with 22rv1-Luc cells left kidney capsule that demonstrate prominent signal metastatic tumors at neck and thigh region on day 89Zr labeled nanocarrier injection.</p>
<p>Supplementary Figure S8. Organ biodistribution presented in (left) %ID/g, and (right) %ID/organ for 89Zr labeled nanocarriers nude mice bearing 22rv1 subcutaneous tumors at 96 h postinjection. (n = 4, mean ± SD)</p>
<p>Supplementary Figure S17. Immunofluorescence CD31 staining of the respective tumor tissue sections using rat anti-mouse antibody indicating vascular development in different phenotypes.</p>
<p>Supplementary Figure S18. BLI of all mice in the cohort inoculated with 22rv1-Luc cells left kidney capsule that demonstrate prominent signal metastatic tumors at neck and thigh region on day [89Zr]PEG-DFB1-TLZ3 injection. Black arrows indicate presence tumors.</p>
<p>Supplementary Figure S10. Organ biodistribution presented in (left) %ID/g, and (right) %ID/organ for 89Zr labeled nanocarriers nude mice bearing LTL-545 patient derived xenograft (PDX) of tumors at 96 h postinjection. (n = 4, mean ± SD)</p>
<p>Supplementary Figure S15. Autoradiographic images of PDX LTL-610 tumor sections from day 1 to 3 post injection 89Zr labeled nanocarriers. H&E staining the respective timepoints are not available.</p>
<p>Supplementary Figure S13. Autoradiographic images and H&E staining of subcutaneous CT26 tumor sections from day 1 to 4 post injection 89Zr labeled nanocarriers. *Indicate the presence necrosis.</p>
<p>Supplementary Figure S3. Ex vivo tumor biodistribution, (a) %ID per gram and (b) organ of nude mice bearing different models including prostate cancer (22rv1, PC3, DU145), colorectal (CT26), pancreatic (BxPC3) at 24h 72 h post-injection [89Zr]PEG-DFB1-TLZ3. The respective (c) uptakes, (d) to muscle ratio, (e) blood ratio the same mice. (n = 4, mean ± SD) (f) Autoradiographic images sections from mouse model preclinical xenograft 72h [89Zr]PEG-DFB1-TLZ3.</p>